Mark J. Levis

26.0k citations

323 papers · 14.5k indexed · 5 hit papers · h-index 63

Hematology top 0.01%
- Acute Myeloid Leukemia Research 288
- Chronic Myeloid Leukemia Treatments 179
- Multiple Myeloma Research and Treatments 29
Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research 123
- Myeloproliferative Neoplasms: Diagnosis and Treatment 45
Molecular Biology top 0.5%
- Protein Degradation and Inhibitors 32
- Retinoids in leukemia and cellular processes 22
Oncology top 1%
Public Health, Environmental and Occupational Health top 0.5%
- Acute Lymphoblastic Leukemia research 49

Co-authors: Donald Small B. Douglas Smith Alexander E. Perl Naval Daver Sabine Käyser Keith W. Pratz Nigel H. Russell Jörge E. Cortes
Cited by: Hematology Genetics Molecular Biology
Journals: Blood (140 papers)Journal of Clinical Oncology (34 papers)Blood Advances (14 papers)
Partner nations: United States Germany Italy

In The Last Decade

Mark J. Levis

311 papers receiving 14.2k citations

Hit Papers

5 papers align trajectories log scale

Peers

Countries citing papers authored by Mark J. Levis

Since Specialization

Citations

This map shows the geographic impact of Mark J. Levis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Levis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Levis more than expected).

Fields of papers citing papers by Mark J. Levis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Levis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Levis. The network helps show where Mark J. Levis may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark J. Levis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark J. Levis Line = papers co-authored together Mark J. Levis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors Blood ·Shirley Mo,Alexander J. Ambinder,Amy E. DeZern,B. Douglas Smith,Ephraim J. Fuchs,Gabriel Ghiaur,Gabrielle T. Prince,Ivana Gojo,Javier Bolaños‐Meade,Jonathan Webster,Lukasz P. Gondek,Richard J. Jones,Tania Jain,Theodoros Karantanos,W. Brian Dalton,Mark J. Levis	2025	0
2	Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide Transplantation and Cellular Therapy ·Amy E. DeZern,Marianna Zahurak,Karen Gloy,Viet Hung Nhu,Heather J. Symons,Kenneth R. Cooke,Carol Ann Huff,Tania Jain,Lode J. Swinnen,Philip Imus,Nina D. Wagner‐Johnston,Richard F. Ambinder,Ivana Gojo,Alexander J. Ambinder,Mark J. Levis,mohamad ali Haddadian,Javier Bolaños‐Meade,Mary Alyce Shirley,Richard J. Jones,Robert A. Brodsky	2025	0
3	A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia Blood Advances ·Mark J. Levis,Alexander E. Perl,Gary J. Schiller,Amir T. Fathi,Gail J. Roboz,Eunice S. Wang,Jessica K. Altman,Trivikram Rajkhowa,Makoto Ando,Stanley Veerin Gunn,Ruth Ann Subach,Eva-Maria Putzier,Timothy Madden,Mary Johansen,K.Y. Cheung,Michael R. Kurman,Catherine C. Smith	2024	9
4	Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia npj Precision Oncology ·Jacob J. Adashek,穣八代,Mark J. Levis	2024	2
5	Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia Blood ·Amy E. DeZern,Marianna Zahurak,Heather J. Symons,Kenneth R. Cooke,Carol Ann Huff,Tania Jain,Lode J. Swinnen,Philip Imus,Nina D. Wagner‐Johnston,Richard F. Ambinder,Mark J. Levis,Leo Luznik,Javier Bolaños‐Meade,Ephraim J. Fuchs,Richard J. Jones,Robert A. Brodsky	2023	18
6	The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia Science Advances ·Theodoros Karantanos,Patric Teodorescu,Brandy Perkins,Kaveh Ostad-Ali-Askari,Gendis Ayu Satiti Irawan,Ravi Varadhan,Bautista Vélez,Trivikram Rajkhowa,Bogdan C. Paun,Challice L. Bonifant,W. Brian Dalton,Lukasz P. Gondek,Alison R. Moliterno,Mark J. Levis,Gabriel Ghiaur,Richard J. Jones	2022	10
7	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemiabreakdown → Journal of Clinical Oncology ·Naval Daver,Alexander E. Perl,Joseph Maly,Mark J. Levis,Ellen K. Ritchie,Mark R. Litzow,James McCloskey,Catherine C. Smith,Gary J. Schiller,Terrence Bradley,Ramón V. Tiu,Kiran Naqvi,Monique Dail,Deanna J. Brackman,Wenjie Liu,Jing Wang,Brenda Chyla,Paul Lee,Jessica K. Altman	2022	123
8	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib Blood Cancer Journal ·Alexander E. Perl,Naoko Hosono,Pau Montesinos,Nikolai A. Podoltsev,Giovanni Martinelli,Nicki Panoskaltsis,Christian Récher,Catherine C. Smith,Mark J. Levis,Stephen A. Strickland,Christoph Röllig,Benjamin Hackl,Wen‐Chien Chou,Je‐Hwan Lee,Hisayuki Yokoyama,Nahla Hasabou,Qiaoyang Lu,Ramón V. Tiu,Jessica K. Altman	2022	27
9	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy Leukemia & lymphoma ·Theodoros Karantanos,Hua‐Ling Tsai,Lukasz P. Gondek,Amy E. DeZern,Gabriel Ghiaur,W. Brian Dalton,Ivana Gojo,Gabrielle T. Prince,Jonathan Webster,Alexander J. Ambinder,B. Douglas Smith,Mark J. Levis,Ravi Varadhan,Richard J. Jones,Tania Jain	2022	8
10	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia Leukemia Research ·Hetty E. Carraway,Yazeed Sawalha,Ivana Gojo,Min-Jung Lee,Sunmin Lee,Yusuke Tomita,Akira Yuno,Alosius Des Afriando Sinuraya,B. Douglas Smith,Keith W. Pratz,Mark J. Levis,Steven D. Gore,Nilanjan Ghosh,Amy E. DeZern,Amanda L. Blackford,Maria R. Baer,Lia Gore,Richard Piekarz,Jane B. Trepel,Judith E. Karp	2021	10
11	Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features npj Precision Oncology ·John-William Sidhom,Barros Km,Evelynn Lienhard,李尚信,Rokuro Hama,В. Я. Распопов,Amy S. Duffield,Michael B. Streiff,Alison R. Moliterno,Philip Imus,Christian B. Gocke,Lukasz P. Gondek,Amy E. DeZern,Alexander S. Baras,Thomas S. Kickler,Mark J. Levis,Eugene Shenderov	2021	21
12	Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN) Blood ·Theodoros Karantanos,Hua‐Ling Tsai,Lukasz P. Gondek,Mark J. Levis,Margaret M. Showel,Amy E. DeZern,Ivana Gojo,Ravi Varadhan,Richard J. Jones,Tania Jain	2020	1
13	The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing Blood Advances ·W. Brian Dalton,Bautista Vélez,Julien de Rosny,Bing Li,Christopher D. Gocke,Joshua Donaldson,Zhijian Xiao,Lukasz P. Gondek,Gabriel Ghiaur,Ivana Gojo,B. Douglas Smith,Mark J. Levis,Amy E. DeZern	2020	38
14	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia Blood Advances ·Paul Milne,Charlotte S. Wilhelm-Benartzi,Michael R. Grunwald,Venetia Bigley,Richard Dillon,Sylvie Freeman,Kathleen Gallagher,M. O. Ibegbunam,Sarah Pagan,Helen Marr,Gail Jones,Anne M. Dickinson,Angela Grech,Alan K. Burnett,Nigel H. Russell,Mark J. Levis,Steven Knapper,Matthew Collin	2019	17
15	Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies Cancer Research ·Mikhail Stashenko,S. Hayley,Li Li,Alice Can Ran Qin,Michelle A. Rudek,Richard J. Jones,Mark J. Levis,Keith W. Pratz,Christine A. Pratilas,Donald Small	2017	32
16	A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia Blood ·Molly Gallogly,У. С. Скрябина,Irfan Sohail,Paolo F. Caimi,Michael Craig,Marcos de Lima,Stanton L. Gerson,Won Moo Kim,Hillard M. Lazarus,Mark J. Levis,Ehsan Malek,Jane A. Little,홍마리아,Willem J. van Heeckeren,William Tse,Brenda Cooper	2017	4
17	A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia Clinical Cancer Research ·Keith W. Pratz,Michelle A. Rudek,Ivana Gojo,Mark R. Litzow,Michael A. McDevitt,Jiuping Ji,Larry M. Karnitz,James G. Herman,Robert J. Kinders,B. Douglas Smith,Steven D. Gore,Hetty E. Carraway,Margaret M. Showel,Douglas E. Gladstone,Mark J. Levis,Hua-Ling Tsai,Gary L. Rosner,Alice P. Chen,Scott H. Kaufmann,Judith E. Karp	2016	38
18	FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia Cancer Research ·S. Hayley,Bao Nguyen,Amy S. Duffield,Li Li,Muhammad Kurniawan Budi Wibowo,Hila Lahav‐Ezra,Patrick A. Brown,Mark J. Levis,Daniel J. Leahy,Donald Small	2014	25
19	Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML Blood ·Zhihong Zeng,Yue Shi,Ismael Samudio,Rui-Yu Wang,Xiaoyang Ling,Olga Frolova,Mark J. Levis,Joshua B. Rubin,Marcelo Juliano Moretto,Elihu H. Estey,Sergej Konoplev,Michael Andreeff,Marina Konopleva	2008	397
20	Novel FLT3 tyrosine kinase inhibitors Expert Opinion on Investigational Drugs ·Mark J. Levis,Donald Small	2003	24

About Mark J. Levis

Mark J. Levis is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Molecular Biology and Oncology, having authored 323 papers that have together received 14.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (288 papers), Chronic Myeloid Leukemia Treatments (179 papers), Chronic Lymphocytic Leukemia Research (123 papers), Acute Lymphoblastic Leukemia research (49 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (45 papers), Protein Degradation and Inhibitors (32 papers), Multiple Myeloma Research and Treatments (29 papers) and Retinoids in leukemia and cellular processes (22 papers). The work is most often cited by research in Hematology (11.3k citations), Genetics (4.3k citations), Molecular Biology (6.8k citations), Oncology (2.0k citations) and Public Health, Environmental and Occupational Health (2.1k citations). Mark J. Levis has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Donald Small, B. Douglas Smith, Alexander E. Perl, Naval Daver, Sabine Käyser, Keith W. Pratz, Nigel H. Russell, Jörge E. Cortes, Richard F. Schlenk and Hagop M. Kantarjian. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Leukemia and Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact